India extends medical devices PLI scheme, relaxes entry criteria

The Centre has announced a significant overhaul of its medical devices Production Linked Incentive (PLI) scheme, extending the initiative through 2032 and introducing sweeping regulatory changes designed to broaden industry participation. The revised scheme removes the previously mandated minimum sales threshold, addressing a key constraint that had limited uptake among smaller and mid-sized manufacturers.

Under the new framework, investment requirements have been lowered across production categories, reducing the financial barriers for companies seeking to establish or expand manufacturing operations in India. The modified structure also introduces higher incentive rates for manufacturers focusing on critical components and advanced medical devices, particularly those addressing domestic healthcare needs and import substitution priorities.

The extension reflects the government's commitment to strengthening India's medical device manufacturing ecosystem, which has faced competition from established overseas producers. By reducing regulatory friction and enhancing financial incentives, policymakers aim to encourage domestic manufacturers to scale operations and develop capabilities in specialized medical technology segments.

The revised scheme is expected to attract both established players and new entrants to the sector, potentially accelerating growth in a market segment identified as crucial for achieving broader healthcare self-sufficiency objectives. Industry observers have indicated that the removal of sales thresholds and lower investment requirements could particularly benefit emerging manufacturers seeking to establish competitive manufacturing bases.